Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Human papillomavirus (HPV) is the primary cause of cervical cancer.
• HPV gene integration leads to E6 and E7 oncogene upregulation.
• E6 and E7 proteins inactivate tumor suppressors p53 and retinoblastoma, promoting malignancy.

Purpose of the Study:

• To explore therapeutic strategies targeting HPV E6 and E7 oncoproteins.
• To review current and developing treatments for HPV-associated cervical cancer.
• To outline the progression of HPV-targeted therapies towards clinical application.

Main Methods:

• Review of existing literature on HPV oncogenesis and therapeutic interventions.
• Analysis of immunotherapies designed to elicit antigen-specific immune responses against HPV E6/E7.
• Examination of siRNA technologies for modulating E6/E7 expression.
• Investigation of proteasome and histone deacetylase inhibitors for indirect targeting of E6/E7.

Main Results:

• HPV E6 and E7 antigens are suitable therapeutic targets due to their presence in cancer cells and absence in normal cells.
• Multiple therapeutic modalities, including immunotherapy, siRNA, and small molecule inhibitors, are under development.
• These therapies aim to neutralize E6/E7 activity or expression, thereby inhibiting cancer progression.

Conclusions:

• Targeting HPV E6 and E7 offers a promising strategy for treating cervical cancer and precursor lesions.
• The development of diverse therapeutic approaches underscores the potential for effective HPV-driven cancer treatment.
• Successful clinical progression and commercialization of these therapies are the ultimate objectives.